Impact of prior immunotherapy on paclitaxel/bevacizumab in advanced non-squamous non-small cell lung cancer [0.03%]
先前免疫治疗对晚期非鳞非小细胞肺癌培美曲塞/贝伐单抗的影响
Agathe Peyret,Clémentine Le Berrurier,Luc Heraudet et al.
Agathe Peyret et al.
Immunotherapy is becoming essential in the management of advanced non-small cell lung cancer (NSCLC); however, the best treatment sequence remains to be determined. Some data suggest that immunotherapy prior to chemotherapy with paclitaxel/...
A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America [0.03%]
东亚与欧洲/北美的小细胞肺癌临床指南、治疗特征和预后的对比研究
Chi-Lu Chiang,Ross Andrew Soo,Tony Mok et al.
Chi-Lu Chiang et al.
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis and accounts for approximately 11% of all lung cancers. Owing to the complex and aggressive nature of the disease, clinical management of SCLC is ...
Case Report: Effectiveness of Inetetamab combined with immunochemotherapy as first-line treatment in two cases of advanced gastric cancer with HER2 expression: a retrospective analysis [0.03%]
个例报告：伊尼妥单抗联合化疗一线治疗HER2阳性晚期胃癌患者疗效回顾性分析
Shan Wu,Miao Zhang,Huaqing Wang
Shan Wu
This retrospective study analyzed the effectiveness of Inetetamab combined with an immunochemotherapy regimen as first-line treatment in two cases of advanced gastric cancer with human epidermal growth factor receptor 2 (HER2) expression. B...
Prognostic modeling for diffuse midline glioma: development and validation of a risk stratification nomogram using SEER and institutional cohorts [0.03%]
基于SEER和机构队列的弥漫内生性桥脑胶质瘤预后模型的建立及验证研究
Ge Zhang,Huandi Zhou,Wanyue Han et al.
Ge Zhang et al.
Background: Diffuse midline glioma (DMG) is a rare and highly aggressive central nervous system tumor with limited treatment options and poor survival outcomes. Reliable prognostic models are urgently needed to guide risk...
Multicenter prospective cohort study on colorectal adenoma recurrence and malignant transformation risk based on integrative medicine: a study protocol [0.03%]
基于整合医学的结直肠腺瘤复发及癌变风险多中心前瞻性队列研究方案
Yi-Fan Hui,Shao-Chen Song,Wen-Jian Zhu et al.
Yi-Fan Hui et al.
Introduction: Colorectal adenoma (CRA), the main precursor of colorectal cancer (CRC), has a high recurrence rate (5-year cumulative: 48 - 68%) and a malignant transformation risk (0.2 - 0.5%). Traditional Chinese Medicin...
Editorial: Immunotherapy and cell therapy for patients with relapsed and refractory acute myeloid leukemia [0.03%]
编者按：复发/难治性急性髓系白血病的免疫和细胞治疗
JingYi Huang,ShiYao Song,Xiaotian Zhang et al.
JingYi Huang et al.
Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease [0.03%]
靶向BCMA的CAR-T细胞治疗后多发性骨髓瘤患者预后的相关因素：体外和髓腔内病变的影响
Ziad Abuhelwa,Fnu Amisha,Wenyi Fan et al.
Ziad Abuhelwa et al.
Introduction: BCMA-directed CAR T-cell therapies have improved outcomes in relapsed and refractory multiple myeloma (MM); however, the majority of patients relapse within 1 to 3 years following treatment. Managing disease...
Case Report: Venetoclax combined with hypomethylating agents for the treatment of newly diagnosed with mixed-phenotype acute leukemia and a literature review [0.03%]
病例报告：委曲霉素与低甲基化药物联合治疗新诊断的混合表型急性白血病及文献回顾
Ruihua Mi,Shuli Guo,Weidong Yang et al.
Ruihua Mi et al.
Objective: To investigate the efficacy and safety of venetoclax (Ven) in combination with hypomethylating agents (HMAs) for the treatment of mixed-phenotype acute leukemia (MPAL). ...
Genetically instrumented circulating metabolites and hepatobiliary cancer risk: A multi-tiered Mendelian randomization and functional interrogation [0.03%]
遗传工具的循环代謝物与肝胆癌风险的关系：多层次孟德尔随机化及功能验证研究
Lin Tuo,Li Ting Yan,Ying Liu et al.
Lin Tuo et al.
Background: Hepatobiliary malignancies-including hepatocellular carcinoma and cholangiocarcinoma-are major causes of cancer-related mortality worldwide, yet their regulatory pathways remain incompletely defined. ...
Cyclophosphamide for severe T-DXd-induced interstitial lung disease in low-HER2 breast cancer: a case report and mechanistic insights [0.03%]
抗HER2低表达乳腺癌T-DXd所致严重间质性肺疾病的环磷酰胺治疗：1例报告及机制探讨
Weichun Zhang,Xiaozhi Li,De Zeng et al.
Weichun Zhang et al.
Background: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) that has shown significant efficacy in treating both HER2-positive and low-HER2 breast cancers. However, interstitial lung disease (ILD) remai...